Show simple item record

Response to: Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al

dc.contributor.authorUgarte-Gil, M.F.
dc.contributor.authorKonig, M.F.
dc.contributor.authorKorsten, P.
dc.contributor.authorBerenbaum, F.
dc.contributor.authorKim, A.H.
dc.contributor.authorSparks, J.A.
dc.date.accessioned2025-10-31T18:32:37Z
dc.date.available2025-10-31T18:32:37Z
dc.date.issued2022
dc.identifier.urihttps://hdl.handle.net/20.500.12805/4715
dc.description.abstractThe viewpoint of Graef et al resonates more each day. In a pandemic where the cries for certainty were met with a flow of mixed early study results, they admonish festina lente (‘make haste slowly‘)! Since Graef, there have been many studies of hydroxychloroquine (HCQ) for treating COVID-19. These include a randomised controlled trial of 150 mild-to-moderate patients and three large observational studies, all inpatient studies that failed to show benefit of HCQ treatment for COVID-19. Now a new inpatient study, with >80% administered HCQ within 24 hours, finds HCQ associated with substantial mortality reduction. Festina lente indeed! A look at HCQ as prophylaxis, where its long half-life can be leveraged, may help...en_US
dc.description.sponsorshipCompeting interests PK reports personal fees from GlaxoSmithKline, Sanofi-Aventis, Pfizer, Abbvie, Novartis Pharma, Eli Lilly and Bristol-Myers Squibb. FB reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, Novartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica and 4P Pharma. AHK reports grants from National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and Rheumatology Research Foundation and personal fees from Exagen Diagnostics, Inc. and GlaxoSmithKline. Drs Liew and Graef have disclosed no conflicts of interest or competing interests. JAS reports grants from NIH/ NIAMS/National Institute of Allergy and Infectious Diseases/Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen and Optum.
dc.formatapplication/pdf
dc.language.isoeng
dc.publisherBMJ Publishing Group
dc.relation.ispartofurn:issn:0003-4967
dc.rightshttps://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectSDG 3en_US
dc.subjectCOVID-19, Its Impact, and Vaccinationen_US
dc.subjectCOVID-19 Impact on Rheumatic Disease Managementen_US
dc.titleResponse to: Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et alen_US
dc.typehttps://purl.org/coar/resource_type/c_545b
dc.identifier.doihttps://doi.org/10.1136/annrheumdis-2020-218683
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.27
dc.type.otherLetter to the editor
dc.identifier.journalAnnals of the Rheumatic Diseases
dc.type.versionhttps://purl.org/coar/version/c_970fb48d4fbd8a85


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://purl.org/coar/access_right/c_abf2
Except where otherwise noted, this item's license is described as https://purl.org/coar/access_right/c_abf2